MENLO PARK, Calif.,
June 19, 2018 /PRNewswire/
-- BioPharmX Corporation (NYSE American: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, has formed a Special Advisory Council of thought leaders
from various disciplines to help the company embrace patient
centricity in its products, pricing and market access
considerations.
The advisors, who bring decades of experience in fields beyond
dermatology – ranging from regulatory pathways to market access and
from infectious diseases to antibiotic resistance – will inform the
company's efforts by providing the kind of strategic expertise
needed to position BioPharmX as a leader in patient-centric
dermatology. The Special Advisory Council will collaborate with
both the company's scientific and medical team and its Medical
Advisory Board, a group of elite dermatologic experts in acne and
rosacea who have been instrumental in guiding BioPharmX in the
treatment of these diseases.
"We are excited about what the future holds for BioPharmX and
are confident that this team of respected scientists and physicians
will enable us to accelerate the next steps in our company's
evolution," said Anja Krammer,
BioPharmX President and Co-Founder. "After years of working on our
pipeline and patent protections for our unique delivery systems, we
now are collaborating with these passionate patient advocates to
help us achieve our goal of becoming truly patient centric.
Ultimately, they will help us put patients at the center of
everything we do."
Patient-centricity has been a decades-long goal for the
healthcare industry. But larger companies have struggled to
retrofit their products and services around patient-centered care
models. BioPharmX, designed to be a more nimble organization, is
committed to ensuring its products are dedicated to the patient,
from developing cosmetically elegant products that are easy to use,
tolerable and with minimal side effects, to making sure those
products are reasonably priced and available to the patients who
seek them.
"There has never been a greater need for patient-centricity in
dermatology," said Dr. Julie Harper,
president of the American Acne and Rosacea Society and member of
the company's Medical Advisory Board. "I look forward to
collaborating with these distinguished colleagues to drive
innovative solutions and improve access to care."
The Special Advisory Council includes:
- R. Todd Plott, MD, an
expert on oral minocycline formulation, clinical trials and
regulation, who holds six patents related to Solodyn®
oral minocycline and was appointed to the FDA Dermatologic &
Opthalmic Drug Advisory Committee 2014-2019.
- Mark D. Kaufmann, MD,
associate clinical professor of dermatology at the Icahn School of
Medicine at Mount Sinai, an expert on market access and formulary,
with extensive experience working with companies to place novel
drugs on appropriate formularies.
- George Zhanel, PharmD,
PhD, professor in the Department of Medical Microbiology and
Infectious Diseases at Max Rady College of Medicine, University of Manitoba, coordinator of antibiotic
resistance in the Departments of Medicine and Microbiology at the
Health Sciences Centre in Winnipeg, and director of the Canadian
Antimicrobial Resistance Alliance. He is an expert on antibiotic
resistance.
- Kenneth J. Tomecki, MD,
vice chairman of the Department of Dermatology at Cleveland Clinic,
an expert on infectious diseases with a passion for
patient-centric care, medical education and clinical
research.
- James J. Leyden, MD,
emeritus professor of dermatology at the University of Pennsylvania. In addition to 50 years
of experience with acne and rosacea, he is an expert on
regulatory issues and has consulted for the Food and Drug
Administration, the Federal Trade Commission and drug regulation
agencies in England, Germany and Austria.
Full biographies of these advisors can be found at the BioPharmX
website.
BioPharmX has successfully completed a phase 2b trial for BPX-011 for acne and is
preparing for phase 3 trials, and has reported positive interim
results from a feasibility study for BPX-04 for rosacea and is
preparing for a phase 2 trial.
About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a Silicon
Valley-based specialty pharmaceutical company, which seeks to
provide products through proprietary platform technologies for
prescription, over-the-counter, and supplement applications in the
health and wellness markets, including dermatology and women's
health. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statements
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. Forward-looking
statements about the company's expectations, plans, intentions, and
strategies, include, but are not limited to, statements regarding
the ability of the Special Advisory Council to provide guidance on
patient-centric care, our ability to prepare for and successfully
execute the phase 3 trial for BPX-01 and the phase 2 trial for
BPX-04, the results of and the size of such trials, strategic
partnering alternatives, the safety and medical effects of BPX-01,
the effect BPX-01 may have on the treatment of acne, the continued
and consistent results in future tests of BPX-01, absence of side
effects of future use of BPX-01 and ability to advance BPX-01
through a successful NDA submission and commercialization. These
forward-looking statements may be identified by words such as
"plan," "expect," "anticipate," "believe," "intend," "should,"
"may" or similar expressions.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the fiscal year
ended Jan. 31, 2018 and our subsequent quarterly reports on
Form 10-Q. Given these risks and uncertainties, you are cautioned
not to place undue reliance on such forward-looking statements. The
forward-looking statements included in this news release are made
only as of the date hereof, and the company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
law.
1 Caution: BPX-01 and BPX-04 are new drugs limited by
U.S. law to investigational use.
View original content with
multimedia:http://www.prnewswire.com/news-releases/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology-300667178.html
SOURCE BioPharmX Corporation